Strategic treatment optimization for hcv (stophcv1): a randomised controlled trial of ultrashort duration therapy for

HIGHLIGHTS

• who: Editing et al. from the Institute for Health Research, or the Department of Health Department of Infectious Disease, Imperial College London, London, NY, UK MRC Clinical Trials Unit, University College London Medical School, London, UK have published the research: Strategic treatment optimization for HCV (STOPHCV1): a randomised controlled trial of ultrashort duration therapy for, in the Journal: (JOURNAL) of 29/07/2021
• how: The authors conducted a multi-centre randomised open-label factorial parallel group non-inferiority trial of adults with mild chronic HCV in 14 UK centres .
• future: This suggests that . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.